Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4921493 | 0.88 | MAPT (0.32) | MAPTCES1 | |
| SCHEMBL4922541 | 0.88 | PLK4 (0.37) | MAPTCES1CSNK2A1 | |
| SCHEMBL4920597 | 0.88 | MAPK1 (0.35) | MAPTALDH1A1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL4919694 | 0.84 | MAPT (0.37) | MAPTALDH1A1HTR2C | |
| SCHEMBL25171507 | 0.83 | MAPT (0.35) | MAPTLMNA | |
| SCHEMBL12925904 | 0.82 | GPR3 (0.46) | MAPTALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL4919466 | 0.82 | MAPT (0.35) | MAPTALDH1A1KDM4EMEN1LMNA | |
| SCHEMBL4913260 | 0.82 | MAPT (0.35) | MAPTHTR2C | |
| SCHEMBL4922933 | 0.82 | MAPT (0.35) | MAPTHTR2C | |
| SCHEMBL4917246 | 0.80 | MCL1 (0.40) | MAPTALDH1A1KDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139824-A1 | DIBENZOTHIOPHENE OXIDE COMPOUND, AND PROCESS FOR PRODUCING THE SAME | SEKINE CHIZU | 2008-06-12 | — | — | US | disclosed |
| US-20070057229-A1 | COMPOUND HAVING PHENYLACETYLENE STRUCTURE, LIQUID CRYSTAL COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC PRODUCT, OPTICAL OR LIQUID CRYSTAL ELEMENT, DIBENZOTHIOPHENE COMPOUND, INTERMEDIATE, AND PROCESS FOR PRODUCING THE SAME | SEKINE CHIZU | 2007-03-15 | — | — | US | disclosed |
| US-7135579-B2 | Dibenzothiophene oxide compound, and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-11-14 | — | — | US | disclosed |
| US-6849202-B2 | COMPOUND HAVING PHENYLACETYLENE STRUCTURE, LIQUID CRYSTAL COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC PRODUCT, OPTICAL OR LIQUID CRYSTAL ELEMENT, DIBENZOTHIOPHENE COMPOUND, INTERMEDIATE, AND PROCESS FOR PRODUCING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-02-01 | — | — | US | disclosed |
| US-20040232384-A1 | Compound having phenylacetylene structure, liquid crystal composition, polymer, optically anisotropic product, optical or liquid crystal element, dibenzothiophene compound, intermediate, and process for producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-11-25 | — | — | US | disclosed |
| US-20020110650-A1 | Compound having phenylacetylene structure, liquid crystal composition, polymer, optically anisotropic product, optical or liquid crystal element, dibenzothiophene compound, intermediate, and process for producing the same | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070057229-A1 | COMPOUND HAVING PHENYLACETYLENE STRUCTURE, LIQUID CRYSTAL COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC PRODUCT, OPTICAL OR LIQUID CRYSTAL ELEMENT, DIBENZOTHIOPHENE COMPOUND, INTERMEDIATE, AND PROCESS FOR PRODUCING THE SAME | CCNT1, CCNA1, CCNT2 | MAPT 86/4885CES1 590/4885ALDH1A1 22/4885 |
| US-20040232384-A1 | Compound having phenylacetylene structure, liquid crystal composition, polymer, optically anisotropic product, optical or liquid crystal element, dibenzothiophene compound, intermediate, and process for producing the same | CCNT1, BPNT1, PEAK1 | MAPT 115/4885CES1 2314/4885ALDH1A1 50/4885 |
| US-20080139824-A1 | DIBENZOTHIOPHENE OXIDE COMPOUND, AND PROCESS FOR PRODUCING THE SAME | CCNT1, CCNA1, BPNT1 | MAPT 69/4885CES1 2839/4885ALDH1A1 42/4885 |
| US-20020110650-A1 | Compound having phenylacetylene structure, liquid crystal composition, polymer, optically anisotropic product, optical or liquid crystal element, dibenzothiophene compound, intermediate, and process for producing the same | CCNT1, NAT1, PEAK1 | MAPT 57/4885CES1 2493/4885ALDH1A1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.